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Abstract
Horizontal gene transfer, mediated by conjugative plasmids, is a major driver of the global rise of antibiotic resistance.
However, the relative contributions of factors that underlie the spread of plasmids and their roles in conjugation in vivo are
unclear. To address this, we investigated the spread of clinical Extended Spectrum Beta-Lactamase (ESBL)-producing
plasmids in the absence of antibiotics in vitro and in the mouse intestine. We hypothesised that plasmid properties would be
the primary determinants of plasmid spread and that bacterial strain identity would also contribute. We found clinical
Escherichia coli strains natively associated with ESBL-plasmids conjugated to three distinct E. coli strains and one
Salmonella enterica serovar Typhimurium strain. Final transconjugant frequencies varied across plasmid, donor, and
recipient combinations, with qualitative consistency when comparing transfer in vitro and in vivo in mice. In both
environments, transconjugant frequencies for these natural strains and plasmids covaried with the presence/absence of
transfer genes on ESBL-plasmids and were affected by plasmid incompatibility. By moving ESBL-plasmids out of their
native hosts, we showed that donor and recipient strains also modulated transconjugant frequencies. This suggests that
plasmid spread in the complex gut environment of animals and humans can be predicted based on in vitro testing and
genetic data.
Introduction
Plasmids can transfer horizontally between bacterial cells,
within and between communities of the same or different
species. They play a crucial role in bacterial ecology and
evolution, because they often carry ecologically relevant
accessory genes that allow bacterial populations to rapidly
adapt to changing environments [1, 2]. Plasmids are
also a major driver of antibiotic resistance evolution [3–5],
and plasmid-encoded resistance determinants such as
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extended-spectrum beta-lactamases (ESBLs) have drawn
particular attention [1, 6, 7]. Understanding the factors
driving the spread of such plasmids is therefore important
for our understanding of bacterial ecology and evolution,
and for managing antibiotic resistance. This is particularly
important in the mammalian gut, an environment that is a
hot-spot of bacterial interaction [8, 9], where microbial
communities consist of multiple species and frequently also
diverse strains of the same species [10]. Despite important
advances in recent decades, our ability to predict which
plasmids will spread, and in which bacterial strains, in
communities of enteric bacteria remains incomplete.
In vitro studies have revealed several key factors that
drive changes in plasmid frequency over time. At the level
of individual cells, plasmid incompatibility and surface- or
entry exclusion can inhibit further plasmid acquisition
[11, 12]. By contrast, some co-residing plasmids can
enhance each other’s stability [13] and transfer [14, 15]. The
host cell’s replication system [16] and other host properties
also influence plasmid replication and stability [17]. Bac-
terial immunity systems such as CRISPR-Cas, or restriction
modification systems (RM system) can eliminate incoming
plasmids [18–21]. At the level of whole populations of
bacteria, plasmid persistence depends on the frequency of
plasmid loss during replication [17, 22], any growth costs
associated with plasmid carriage [23, 24], and rates of
horizontal acquisition [25]. Thus, both plasmid- and host-
properties can influence plasmid stability in a cell and both
a horizontal and a vertical component together can con-
stitute the change in plasmid frequency over time, which we
have defined as ‘plasmid spread’ for this study. Save for
some notable exceptions [26, 27], plasmid spread has
mostly been studied with plasmids not directly relevant for
antibiotic resistance in nature/clinical settings, or with
individual plasmids that have been introduced into well-
defined model strains [11–13, 17, 18, 25, 28, 29]. There-
fore, quantitative information about the relative contribu-
tions of plasmid- and host-determined properties to the
spread of clinical plasmids from their native hosts would
improve our overall understanding of horizontal gene
transfer and bacterial evolution.
In addition to the biotic factors above, local abiotic
conditions can play a key role in plasmid spread, potentially
making it challenging to translate findings about plasmid
dynamics in well-mixed in vitro conditions to natural or
clinical settings. For example, some plasmids transfer more
efficiently when bacteria are settled on surfaces, whereas
others do so in well-mixed environments [30, 31]. Local
environmental conditions, such as nutrient availability [27],
can also impact the spread of mobile genetic elements by
modulating the densities of interacting partners [2], influ-
encing population structure [32], imposing physiological
stress [33], or by modifying selection for plasmid-encoded
traits [34]. Thus, plasmid spread in the natural environment
of the mammalian gastrointestinal tract may differ from that
observed in vitro. Most quantitative information about
plasmid transfer and population dynamics comes from
in vitro studies, whereas information about plasmids in the
mammalian gut relies primarily on genomic studies
[35–37], which lack direct observations of the dynamics and
drivers of plasmid spread. Therefore direct, quantitative
observations of plasmid spread in vivo, and comparison
with classic types of in vitro experiments, would help
translate findings from the laboratory back to nature. We,
and others [38–41], have previously used mouse models to
study processes that limit or boost plasmid spread in the gut
[42–46]. These studies, however, were limited to laboratory
strains and single conjugative plasmids without clinical
relevance, with the exception of a single ESBL-plasmid
used in [44]. To our knowledge, there are no studies that
compare plasmids and their transfer dynamics quantitatively
in vivo and in vitro.
Here, we use clinical E. coli strains and their natively
associated ESBL-plasmids to test for variable plasmid
spread among different bacteria/plasmid combinations,
both in vitro and in mice. We combine these experimental
data with bioinformatic analyses, identifying genetic
determinants that influence plasmid spread in the absence
of antibiotic selection. We chose to work with E. coli
because some important commensal and pathogenic bac-
teria in the gastrointestinal tract come from the family
Enterobacteriaceae, including some of the most important
pandemic ESBL-producing strains [1, 6, 7, 47]. They
often carry plasmids of the incompatibility groups IncF
and IncI, which have low copy number and narrow host
range [6, 48]. Our in vitro data showed the final fre-
quencies of ESBL-plasmid-carrying recipient strains
(transconjugants) varied greatly and were determined by
plasmid, donor and recipient effects. As expected for
conjugative plasmid transfer, the lack of the (tra) genes
[49–51], which are well known to be required for con-
jugation, in three out of the eight clinical ESBL-plasmids
tested, had the biggest impact on plasmid spread. Never-
theless, the donor and recipient strains also had a statis-
tically significant effect on final transconjugant
frequencies. Overall, our in vitro data qualitatively pre-
dicted plasmid spread in the antibiotic-free murine model
for gut colonisation.
Materials and methods
Strains and growth conditions
We used eight ESBL-plasmid positive E. coli strains as
plasmid donors (D1-D8). They were sampled from
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patients in a transmission study at the University Hospital
Basel, Switzerland, and their ESBL-plasmids reflect
relevant vectors of ESBL mediated drug resistance [52].
This collection comprised strains belonging to sequence
types (ST) ST117, ST648, ST40, ST69, ST80, ST95,
ST6697 and the very common ESBL sequence type
ST131. We worked with 4 ESBL-plasmid negative reci-
pient strains: RE1, a mouse-derived E.coli strain cured of
its native IncI1 plasmid [45]; RE2 and RE3, two clinical
E. coli isolates from healthy patients [52, 53]; and RS, the
Salmonella enterica Typhimurium strain ATCC 14028
(RS). A comprehensive list of the plasmids found in these
strains is given in Supplementary Table S1. Marker
plasmids were introduced by electroporation, to mark
recipients with either pACYC184 (New England Biolabs)
encoding Chloramphenicol (Cm) resistance (except for
RS, having chromosomal Cm resistance marT::cat [42])
or pBGS18 [54] encoding Kanamycin (Kan) resistance.
Plasmid-borne resistance markers have their limitations,
as they may interact with other plasmids present in these
strains and potentially also affect their spread. Here, this
effect seems minimal (Supplementary Fig. S1). Unless
stated otherwise, we grew bacterial cultures at 37 °C and
under agitation (180 rpm) in lysogenic broth (LB) med-
ium, supplemented with appropriate amounts of anti-
biotics (none, 100 µg/mL Ampicillin (Amp), 25 µg/mL
Cm in vitro and 15 µg/mL Cm prior to in vivo experi-
ments, 50 µg/mL Kan). We stored isolates in 25% glycerol
at −80 °C.
Antibiotic resistance profiling
We used microdilution assays with a VITEK2 system
(bioMérieux, France) to determine the minimum inhibitory
concentrations (MIC). MIC breakpoints for ESBLs were
interpreted according to EUCAST guidelines (v8.1). In
addition, we confirmed resistance mechanism phenotypi-
cally, using ROSCO disk assays (ROSCO Diagnostica,
Denmark), and/or genotypically with detection of CTX-M1
and CTX-M9 groups using the eazyplex Superbug assay
(Amplex, Germany).
In vitro conjugation experiment
To determine plasmid spread, which can include a vertical
(clonal expansion) and a horizontal (conjugation) compo-
nent, we calculated the final transconjugant frequency, which
is the recipient population that obtained an ESBL-plasmid
(transconjugants/(recipients+transconjugants), T/(R+T)), in
a high throughput, 96-well plate-based assay. Donor and
recipient populations grew overnight with or without Amp,
respectively. We washed the independent overnight cultures
by spinning down and resuspending and added ~1 µL of 6.5-
fold diluted donor and recipient cultures into 150 µL fresh
LB with a pin replicator (total ~1000-fold dilution, aiming to
reach approximately a 1:1 ratio of donor and recipient).
These mating populations grew for 24 h in the absence of
antibiotics and were only shaken prior to hourly optical
density (OD) measurements (Tecan NanoQuant Infinite
M200 Pro). To determine the final cell densities, we plated
the mating cultures at the end of the conjugation assay on
selective LB-plates. In the first conjugation experiment,
referred to as the 1st generation in vitro experiment, where
the clinical strains transferred their native plasmids to reci-
pients, we selected for donors+transconjugants with Amp,
for recipients+transconjugants with Cm (E. coli recipients
carried pACYC184-Cm and RS chromosomal marT::cat)
and for transconjugants with Amp+Cm. For a second,
separate conjugation experiment, referred to as the 2nd
generation in vitro experiment, we chose a subset of trans-
conjugants generated in the 1st generation in vitro experi-
ment as new plasmid donors. Transconjugants isolated from
the 1st generation experiment were frozen and regrown
before the 2nd generation experiment. The resulting cultur-
ing steps make differences between the 1st and 2nd gen-
eration experiments due to transient plasmid de-repression in
transconjugants unlikely [55, 56]. Transconjugants and
recipients of the clone type RE3 were omitted because of the
size of the experiment, and transconjugant RE2 carrying
p1B_IncI had to be excluded as plasmid donor due to
insufficient freezer stocks. We selected for donors with Cm,
for recipients with Kan (recipients carried pBGS18-Kan) and
for transconjugants with Kan+Amp. A single transconjugant
colony would be equivalent to 20 CFU/mL, which approx-
imates our detection limit. We performed experiments
with E. coli recipients and S. Typhimurium recipient RS
as independent experiments and the 1st generation in vitro
(n= 4–6) and 2nd generation in vitro (n= 6) experiments
each in two replica blocks.
The plasmids in our conjugation experiments could
either be transferred in the liquid growth phase or after
plating on selective plates (surface mating). To assess the
extent of surface mating we performed an additional
experiment, where we treated donors and recipients as
above but grew them in separate liquid cultures, instead of
mixed cultures, only mixing them immediately before
plating on selective LB-plates. To make a direct comparison
between some of the donor-plasmid-recipient combinations
used in the 1st generation and 2nd generation in vitro
experiments, we performed a conjugation experiment as
described above with D1 (with and without pACYC184)
and transconjugants RE1 and RS carrying plasmid 1B_IncI,
isolated from the 1st generation in vitro experiment, as
plasmid donors.
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In vitro plasmid cost experiment and other growth
rate measurements
To investigate the effect of ESBL-plasmid carriage on
bacterial growth in absence of antibiotics, we measured the
growth rate of transconjugants and recipients. Per donor and
recipient combination, we used three transconjugants, four
replicates each, obtained from independent mating popula-
tions of the 1st generation in vitro experiment. Transcon-
jugants for which we did not store three independent
transconjugants were excluded from this analysis. We grew
bacterial cultures in the absence of antibiotics overnight and
diluted them 150-fold by transfer with a pin replicator to a
96-well plate, containing 150 µL fresh LB per well. We
incubated the cultures without shaking and estimated
growth rates of recipients and transconjugants based on ten
manual OD measurements over 24 h. We estimated growth
rates (h−1) using the R package Growthcurver [57]. We
expressed plasmid cost as the growth rate of transconjugants
relative to the corresponding ESBL-plasmid free recipient.
Transconjugants have experienced longer growth under
laboratory conditions than recipients (conjugation experi-
ment). To verify that this did not affect our estimates of
plasmid cost, we conducted a third growth rate experiment.
Prior to this experiment, recipients were grown under the
same conditions as in the conjugation experiment but
without donor strains. We then measured and compared the
growth rates of these strains and the original recipients that
had not undergone the additional culturing step (Supple-
mentary Fig. S2).
Other growth rate measurements (Supplementary
Figs. S2, S3) were performed as follows: We grew bacterial
cultures with appropriate antibiotics overnight, washed and
diluted them ~1000-fold. For the growth measurements,
bacteria grew in the absence of antibiotics and the plate
reader measured OD every hour for 24 h. Again we esti-
mated growth rates (h−1) using the R package Growthcurver
[57].
In vivo experiments
We have previously established a murine model for enter-
obacterial pathogen infection [58] that allows the tracking
of plasmid dynamics [42–46]. For conjugation experiments,
we used 8–16 week old C57BL/6 mice that contain an oligo
microbiota allowing colonisation of approximately 108 E.
coli per gram faeces [59]. E. coli stool densities of up to 108
CFU/g have also been detected in healthy human volunteers
[53]. We infected 7–10 mice per treatment group (minimum
of two independent experiments; no antibiotic pre-treat-
ment) orogastrically with ~5 × 107 CFU of RE2 or RE3,
carrying marker plasmid pACYC184 and 24 h later with
~5 × 107 CFU of either D4, D7 or D8. Faeces were collected
daily, homogenised in 1 mL of PBS with a steel ball by a
Tissue Lyser (Qiagen) at 25 Hz for 1 min. We enumerated
bacterial populations by selective plating on MacConkey
media (selection for donors+transconjugants with Amp
(100 µg/mL), for recipients+transconjugants with Cm (15
µg/mL) and for transconjugants with Amp+Cm) and cal-
culated final transconjugant frequencies T/(R+T).
For competition experiments we infected 8–16-week-old
C57BL/6 oligo microbiota mice orogastrically with a 1:1
mixture of both competitor strains (~5 × 107 CFU total; no
antibiotic pre-treatment). We collected faeces and enumer-
ated bacterial populations daily. We plated bacteria on
MacConkey agar containing Cm and replica-plated on
media containing Cm, Kan, and Amp to select the transfer
deficient transconjugants. A change in fitness conferred by
plasmid carriage is reflected in the relative frequency of
recipients to transconjugants (R/T).
Prior to all infections, we subcultured the overnight
cultures (LB containing the appropriate antibiotics) for 4 h
at 37 °C without antibiotics (1:20 dilution) to ensure equal
densities of bacteria. Cells were washed in PBS and intro-
duced into mice. All infection experiments were approved
by the responsible authority (Tierversuchskommission,
Kantonales Veterinäramt Zürich, license 193/2016 and
license 158/2019).
Sequencing, assembly, annotation
We sequenced all donor and recipient strains with Illumina
MiSeq (paired end, 2 × 250 bp), Oxford Nanopore MinION
and PacBio Sequel methods. We produced hybrid assem-
blies with Unicycler [60] (v0.4.7) and used the most con-
tiguous assemblies (Oxford Nanopore—Illumina for
D1, D2, D4, D6, D7, D8 and Pacbio Sequel—Illumina for
D3, D5, RE1, RE2, RE3). Manual curation involved
removing contigs smaller than 1kB, and sequences up to 5
kB that mapped to the own chromosome. We performed
quality control by mapping the paired end Illumina reads to
the finished assemblies using samtools (v1.2) and bcftools
(v1.7) [61, 62]. For recipient RS, the ancestral strain was
sequenced with Illumina (2 × 150 bp), and mapped against
the reference sequence, downloaded from NCBI Genbank
under the accession numbers NZ_CP034230.1 and
NZ_CP034231.1.
To study the genetic contribution to the observed varia-
tion in plasmid spread, we sequenced various transconju-
gants from the 1st and 2nd generation in vitro experiments
as well as the in vivo transfer experiment (Supplementary
Table S2). In vitro: three clones from independent mating
populations for RE3 carrying plasmid p4A_IncI or
p8A_IncF and one clone for the other transconjugants. In
vivo: eight clones of RE3 carrying p4A_IncI isolated from
five mice on day 7 post donor infection, and eight clones of
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RE3 carrying p8A_IncF isolated from six mice on day 2
(1 clone), day 6 (3 clones), or day 7 (4 clones) post donor
infection. Resequencing was performed on an Illumina
MiSeq (paired end, 2 × 150 bp) and we mapped the reads to
the closed assemblies of respective donor and recipient
strains using the breseq pipeline (v 0.32.0) [63]. Mutations
or indels shared by all re-sequenced strains were treated as
ancestral (Supplementary Table S2).
To investigate the transfer of plasmid p8C_IncBOKZ,
we screened 3–5 transconjugants from independent mating
populations per conjugation pair (Supplementary Table S2).
We performed PCRs with primers specific to IncB/O and
IncK plasmids [64], (5′ to 3′): MRxeBO_K_for: GAATG
CCATTATTCCGCACAA and MRxeBO_K _rev; GTGAT
ATACAGACCAT-CACTGG).
To extract a chromosomal alignment of the E. coli donor
and recipient strains, we concatenated the genes returned by
core genome Multi-Locus Sequence Typing (cgMLST) for
all strains. We used the chewBBACA software to type these
strains according to the Enterobase cgMLST scheme
[65, 66]. We inferred the phylogenetic tree using BEAST2
[67], with an HKY substitution model, a tight prior on the
mutation rate (constrained around the E. coli mutation rate
of 10−4 mutations per genome per generation, as estimated
by Wielgoss et al. [68], and assuming 100–10,000 genera-
tions per year), and a birth–death tree prior (priors are listed
in Supplementary Table S3). The timing of the tree was
additionally informed by the sampling dates of the strains:
For clinical donor strains this corresponded to the isolation
date in the hospital; recipient RE1 was isolated from a
mouse co-infected with Salmonella on 17.06.2007; and for
recipients RE2 and RE3 we assumed the start of the
3-month study conducted by Wotzka et al. [53], i.e.
30.01.2015. We performed bacterial genome annotation
using Prokka [69], and determined the sequence type (ST)
using mlst (Torsten Seemann, https://github.com/tseemann/
mlst), which makes use of the PubMLST website (https://
pubmlst.org/) developed by Keith Jolley [70]. Phylogroups
were assigned using ClermonTyper [71].
We determined genomic features using a range of
bioinformatic tools, and by BLAST comparison against
various curated databases. Plasmid replicons and resistance
genes were identified using abricate (Torsten Seemann,
https://github.com/tseemann/abricate) with the Plas-
midFinder [72] and ResFinder [73] databases respectively.
We located phages using PHASTER [74] (listing only those
marked as ‘complete’), type 6 secretion systems using
SecReT6 [75], virulence genes using the Virulence finder
database [76], toxin–antitoxin (TA) systems using the
database TADB 2.0 [77], and CRISPR-Cas loci using
CRISPRCasFinder [78]. We found restriction-modification
(RM) systems using the grep function on the term
‘restriction’ in the general feature format files from prokka,
and verified them with the RM-database Rebase [79]. To
determine the presence/absence of IncF and IncI transfer
genes, we constructed our own database as a reference. IncF
transfer genes were taken from the supplementary material
of Fernandez-Lopez et al. [80], IncI1 transfer genes from
plasmids R64 using the annotations by Komano et al. [49],
and IncIγ transfer genes from the plasmid R621a annotated
by Takahashi et al. [50].
Construction of non-transferrable plasmids
For the in vivo competition experiments, we generated non
transferrable plasmids for three independent transconjugants.
We deleted their origin of transfer (oriT) region using the
lambda red recombinase system with pKD4 as template for
the Kan resistance marker [81]. The following primers were










CC). We verified all mutants by PCR (IncI1_oriT _val_f:
AGTTCCTCA-TCGGTCATGTC, IncI1_oriT_val_r: GAAG
CCATTGGCACTTTCTC, D25_oriT_val_fw: CATACAGG-
GATCTGTTGTC and D25_2_oriT_ver_rv: CAGAATCAC-
TAT-TCTGACAC) and experimentally by loss of transfer
function.
Statistical analyses
For in vitro experiments we performed analyses using R
(version 3.4.2). The effects of donor, recipient and plasmid
on final transconjugant frequency were analysed with either
a two-way ANOVA (1st generation in vitro experiment
with factors donor-plasmid pair and recipient) or a three-
way ANOVA (2nd generation in vitro experiment with
factors donor, plasmid, recipient). For the 1st generation
in vitro experiment, we excluded strain–plasmid pairs
which did not result in transconjugants (D2, D3, D7) and
recipient RS from this analysis. When single replicates for a
given donor–recipient combination lacked transconjugants
(D5 and D6), we assigned these replicates a final trans-
conjugant frequency at the detection limit of 10−8. The data
of the 2nd generation in vitro experiment were not fully
factorial. To enable testing of interactions, we therefore
performed two 3-way ANOVAs: one excluding plasmid
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p1B_IncI and one excluding donor RE2, for which
we had to take the two replicate blocks into account:
P < 0.001). For two replicate populations (RS self–self
transfer with p1B_IncI), we had higher counts on plates
selecting for transconjugants than on plates selecting for
recipients+transconjugants and replaced the resulting
negative CFU/mL for recipients with 0 CFU/mL (we
assume the higher count on selective agar reflects mea-
surement error, given the true frequency of plasmid-
carrying cells cannot exceed 1.0).
For statistical comparisons derived from in vivo experi-
ments, Kruskal–Wallis tests were performed with Dunn’s




As potential ESBL-plasmid donors we used eight clinical
E. coli strains (D1-D8), which were selected at the
University Hospital Basel to be representative for the clini-
cally relevant diversity of ESBL-plasmid positive strains.
We chose four recipient strains susceptible to β-Lactam
antibiotics, of which three are E. coli (RE1-RE3) and one
S. Typhimurium (RS, Supplementary Fig. S4, Supplementary
Table S4). Sequence analysis revealed a large phylogenetic
diversity, with donor strains belonging to phylogenetic
groups B1, B2, D or its subgroup F, and recipients to either
B2 or A (Fig. 1). We also observed diverse accessory traits
such as bacterial immunity systems (Supplementary Fig. S5)
and virulence genes (Supplementary Fig. S6). All but two
strains encode type 6 secretion systems (T6SS), and strain
D4 shows an enteropathogenic virulence profile. Each strain
carries at least one and up to eight plasmids of various
incompatibility groups (Supplementary Fig. S7, Table S1).
Every donor strain harbours a single antibiotic-resistance
plasmid (the ESBL-plasmid), either of the plasmid family
IncI or IncF (Table 1) and displayed an ESBL-resistance
phenotype (Supplementary Table S4). All strains encode
numerous intact prophage sequences in their chromosome
(Supplementary Fig. S8) and we found P1-like phages, i.e.
prophages that move like plasmids in their lysogenic phase
[82, 83], in various strains (Supplementary Fig. S9). ESBL-
plasmid p2A_IncF carries a SPbeta-like prophage (68.4 kB),
which encodes all 12 resistance genes of that plasmid. With
the exception of p3A_crypt and pRE3B_crypt, all plasmids
bigger than 35 kB carry plasmid addiction systems [22] (TA
systems, Supplementary Fig. S10).
Time
Fig. 1 Phylogenetic tree of the E. coli donor and recipient strains,
inferred using Bayesian inference on a core genome alignment.
Strain names at the tips are coloured by E. coli phylogroup. The S.
Typhimurium recipient RS was not included in the phylogeny, but
listed here to allow comparison of the plasmid content. RE1–3 denotes
the three E. coli recipients and D1–8 denotes the eight donors. Bars on
internal nodes indicate the 95% highest posterior density interval of the
node age in years, numbers indicate the posterior probability for a
given bifurcation. Blue rectangles show that a plasmid with the indi-
cated IncF or IncI replicon (incompatibility marker) is present in that
strain. A red dot indicates the replicon(s) present on the ESBL-plasmid
in each strain. Coloured letters indicate the E. coli phylogroup.
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Plasmid spread in the absence of antibiotics varies
depending on the clinical donor and the recipient
strain
To test whether the spread of ESBL-plasmids in recipient
populations varied depending on the identity of donor
(clinical isolates, each with different ESBL-plasmids) and
recipient bacteria, we first performed conjugation experi-
ments with all possible donor–recipient combinations in the
absence of antibiotics (referred to as 1st generation in vitro
experiment). We used the final transconjugant frequency,
i.e. the fraction of the recipient population that carried the
ESBL-plasmid after 24 h, to measure plasmid spread. The
highest final transconjugant frequency (~0.1%) was
achieved when plasmid p4A_IncI spread in populations of
recipient RE3. Five of the eight ESBL-plasmids transferred
at detectable levels to more than one of the E. coli reci-
pients and their final transconjugant frequencies spanned
five orders of magnitude (Fig. 2A, Supplementary
Fig. S11). The average final transconjugant frequency
varied depending on the donor–plasmid pair and among
recipient strains (two-way ANOVA excluding D2, D3, D7
with non-conjugative ESBL-plasmids, effect of donor–
plasmid pair: F4,66= 87.665, P < 0.01, effect of recipient:
F2,66= 5.439, P < 0.01). The variation among donor–
plasmid pairs depended also on the recipient (donor-plas-
mid pair × recipient interaction: F8,66= 3.164, P < 0.01).
Although these ESBL-plasmids are natively associated
with E. coli, they reached comparable maximal transcon-
jugant frequencies in the RS (S. Typhimurium) recipient
populations (Fig. 2B). With RS, variation across donor–
plasmid pairs was similar to that obtained with E. coli
recipients, with the exception of p6A_IncI, which did not
transfer to recipient RS.
The pili of type IncI and IncF plasmids support plasmid
transfer on solid surface and in liquid growth environment
[30, 84]. The protocol of our in vitro experiment potentially
allowed for both liquid- and surface- (after plating) mating.
To determine whether surface mating contributed sig-
nificantly to transfer among these strains in these condi-
tions, we performed a separate experiment which only
allows for surface mating, for a subset of donor–recipient
combinations (Supplementary Fig. S12). In this experiment,
only p1B_IncI and p4A_IncI transferred from donor to
recipient, resulting in transconjugant frequencies ranging
from 10−8 to 10−5, in a recipient-dependent manner (two-
way ANOVA excluding D6, D8 and RS: effect of recipient:
F2,20= 34.29, effect of donor–plasmid pair: F1,20= 12.88,
P < 0.01 in both cases). This suggests that plasmid transfer
in our 1st generation in vitro experiments took place pri-
marily during the 24-h liquid-growth phase, although
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Plasmid, donor and recipient lead to variation in
plasmid spread
In the 1st generation in vitro experiment (Fig. 2), where we
investigated the spread of ESBL-plasmids from their native
hosts, each plasmid was present in a single donor. There-
fore, we could not separate the contributions of plasmid and
donor strain to the observed variation of plasmid spread. To
do so, we performed a second conjugation experiment
(referred to as the 2nd generation in vitro experiment) with
plasmids that showed notable plasmid transfer in the 1st
generation in vitro experiment. We held conditions identical
to the 1st generation in vitro experiment, but in the 2nd
generation in vitro experiment each donor strain back-
ground carried one of several ESBL-plasmids and each
ESBL-plasmid was represented in multiple donor strains.
Specifically, we used eight transconjugants isolated from
the 1st generation in vitro experiment as plasmid donors and
three of the same recipient strains (Fig. 3, Supplementary
Fig. S13). The final transconjugant frequency varied among
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RS
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Fig. 2 ESBL-plasmids spread at variable rates in the absence of
antibiotics (1st generation in vitro experiment). Plasmid spread was
measured as the final transconjugant frequency, i.e. the ratio of the
recipient population carrying the ESBL-plasmid (T), relative to the
total of plasmid-free (R) and plasmid carrying (T) recipient popula-
tions. Final transconjugant frequency is shown for recipient
populations of E. coli strains RE1-3 (A) and S. Typhimurium strain RS
(B). Circles represent independent replicates (n= 4–6) and the beams
are mean values ± standard error of the mean (SEM). The detection
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Donor:
Fig. 3 Final transconjugant frequency depends on donor,
recipient, and plasmid (2nd generation in vitro experiment). Eight
transconjugants isolated from mating assays in the 1st generation
in vitro experiment (Fig. 2), used here as plasmid donor strains,
transferred their plasmid to three different recipients. Circles represent
independent replicates (n= 6), the beams are mean values ± SEM and
different plasmids are indicated in colour. The detection limit was at
~10−8. Total population densities can be found in Supplementary
Fig. S13. Donor RE2 carrying plasmid p1B_IncI was excluded, see
‘Methods'.
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donor strains and among plasmids (three-way ANOVA with
plasmid, excluding p1B_IncI, donor and recipient as fac-
tors, effect of donor strain: F2,90= 150.133, P < 0.001,
effect of plasmid: F1,90= 49.717, P < 0.001). Variation
among plasmids depended on both, the recipient and the
donor strain (donor strain × plasmid interaction: F2,90=
96.352, P < 0.001; recipient × plasmid interaction: F2,90=
29.610, P < 0.001). For instance, when the donor and reci-
pient strains were both RS, both IncI ESBL-plasmids yiel-
ded remarkably high final transconjugant frequencies of
40%. A second analysis supported variation among donor
strains and plasmids and that variation among plasmids
depended on recipient and donor strain (three-way ANOVA
excluding RE2, effect of donor strain: F1,93= 560.269, P <
0.001, effect of plasmid F2,93= 156.075, P < 0.001, reci-
pient × plasmid interaction: F4,93= 26.104, P < 0.001,
donor strain × plasmid interaction: F2,93= 3.999, P=
0.022). As in our 1st generation in vitro experiment, aver-
age final transconjugant frequencies also varied among
recipients (P < 0.001 for effect of recipient in both three-
way ANOVAs). Thus, the final frequency of transconju-
gants depended on donor strain, plasmid, and recipient.
Also, we found relatively high final transconjugant fre-
quencies when donor and recipient were plasmid+/plasmid-
versions of the same strain (Fig. 3, self–self transfer).
For some plasmid–recipient combinations, we noticed
that replacing the native donor strains with transconjugants
from the 1st generation in vitro assay (primary and
secondary plasmid transfer, respectively) led to large
differences in final transconjugant frequencies (Figs. 2
and 3). For a subset of strains, we tested whether these
resulted solely from the substitution of the native donor
strain (D1) with a secondary donor strain (RE1 or RS,
Supplementary Fig. S1). When RE1 or RS acted as donor
strain for plasmid p1B_IncI, transconjugant frequencies of
RE1 carrying p1B_IncI increased 45-fold and 112-fold,
respectively, compared to when p1B_IncI was transferred
from its native donor strain D1. When both donor and
recipient were RS, the final transconjugant frequency
increased 2800-fold compared to transfer of plasmid
p1B_IncI from its native host D1 to RS. This shows plasmid
transfer from a secondary bacterial host can differ strongly
from its transfer from the initial host.
ESBL-plasmids can spread rapidly in vivo, with
efficiencies corresponding to in vitro trends
To test the effect of plasmid-donor pair and recipient strain
on plasmid spread in a complex environment, we performed
conjugation experiments in gnotobiotic mice with a defined
multispecies microbiota [59] over 7 days and in the absence
of antibiotics. This resident microbiota allows colonisation
of ~108 E. coli per gram faeces, E. coli densities repre-
sentative of the guts of some humans and animals [10, 53].
We used three clinical donors (D4, D8 and D7), and two
recipients (RE2 and RE3, Fig. 4), a subset of strains that
reflects diversity in plasmid type (that is, incompatibility
group and transfer efficiency in vitro; Figs. 1, 2), and in
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Fig. 4 ESBL-plasmids can spread in the gut in the absence of
antibiotic selection.We measured the spread of three plasmids as final
transconjugant frequency in two distinct recipient populations, A RE2
and B RE3, and enumerated transconjugants in faeces by selective
plating. Dotted lines indicate the detection limit for selective plating.
Circles represent independent replicates (n= 7 for RE2 conjugations;
n= 7 for D4-RE3; n= 10 for D8-RE3 and D7-RE3), lines show the
median and different donor-plasmid pairs are indicated in colour.
Kruskal–Wallis test p > 0.05 (ns), p < 0.05 (*), p < 0.01 (**), p < 0.001
(***), p < 0.0001 (****). Total population densities can be found in
Supplementary Fig. S14.
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genetic properties of the strain (that is, variable virulence
factors, phages or other accessory genes; Fig. 1, Supple-
mentary Figs. S6, S8, S5).
The variation of ESBL-plasmid spread in vivo was in
qualitative agreement with the 1st generation in vitro
experiment. As in the 1st generation in vitro experiment
(Fig. 2) for recipient RE3 we observed highest transconju-
gant frequencies with plasmid p4A_IncI followed by
p8A_IncF and no transconjugants with p7A_IncF (Fig. 4,
Supplementary Fig. S14). Furthermore, the final transcon-
jugant frequency with plasmid p4A_IncI was higher with
RE3 than RE2 both in vivo and in vitro (see Fig. 4A,B, blue
dots, and Fig. 2). Lastly, the final transconjugant fre-
quencies with p8A_IncF were similar for both recipient
populations (Fig. 4A,B, purple dots, and Fig. 2). Because
the final frequency of RE3 carrying p4A_IncI (1%) was
already reached at day 1, we re-performed this conjugation
experiment, sampling more densely in time and found the
final transconjugant frequency to be established already 8 h
after the orogastric introduction of donor D4 (Supplemen-
tary Fig. S15). This rapid increase in transconjugant fre-
quency was followed by a 6-day plateau, which may result
from the simultaneous decrease of recipient and transcon-
jugant populations over time (Supplementary Fig. S14).
Indeed, direct competition experiments in vivo (Supple-
mentary Fig. S16) confirmed the competitive advantage of
donor D4 over RE3. This fitness benefit may be explained
by the difference in growth rate, as estimated in vitro
(Supplementary Fig. S3).
In vitro, we found that plasmid spread from donor strains
and from transconjugants to recipient strains could vary by
several orders of magnitude (Supplementary Fig. S1). Such
differences in plasmid spread from primary and secondary
donor could also be present in vivo. However, with the
exception of RE3 carrying p4A_IncI, the transconjugant
populations were minor compared to the size of the donor
populations throughout the in vivo experiment (Supple-
mentary Fig. S14). Thus, for plasmid spread to be domi-
nated by transfer from transconjugants, plasmid transfer
rates from transconjugants would need to be 104-fold higher
than transfer rates from the donor strain.
No cost of ESBL-plasmid carriage detected and
variable horizontal plasmid transfer probably drives
variation of plasmid spread in vitro and in vivo
The observed variation of final transconjugant frequencies
in vitro and the plasmid dynamics in the mouse gut could
potentially be explained by variable rates of horizontal
plasmid transfer, or by variable rates of clonal expansion of
transconjugants (driven by variable effects of the plasmid
on bacterial growth depending on the plasmid or recipient
strain). To investigate this, we first tested whether these
plasmids were associated with growth costs for ten strain-
plasmid combinations in vitro. We estimated plasmid
growth cost as the growth rate of transconjugants relative to
their respective plasmid-free recipient strain, and in this
experiment, we found no significant effect of plasmid car-
riage on bacterial growth rates for the tested strains
(Fig. 5A,B, Student’s t test for E. coli hosts and Wilcoxon
Rank Sum Test for S. Typhimurium, P > 0.05 in all cases,
before and after Holm’s correction for multiple testing).
This suggests variable rates of clonal expansion of trans-
conjugants relative to recipients are unlikely to explain the
variation in final transconjugant frequencies we observed
(Fig. 2). Consistent with this, we found no correlation
between average final transconjugant frequencies (for the
combinations tested in the experiment in Fig. 2A) and
average growth rate difference between transconjugants and
recipients (Pearson r2= 0.58, P= 0.18).
An alternative explanation for the observed variation of
final transconjugant frequencies across different plasmid/
bacteria combinations is variation of horizontal transfer
rates. To verify that horizontal transfer contributed
substantially to observed final transconjugant frequencies,
we calculated whether clonal expansion of transconjugants,
after a single transfer event, would have been sufficient
to explain observed final transconjugant frequencies in
our in vitro assay (Fig. 2). This was only the case for
S. Typhimurium recipients carrying p1B_IncI and
p8A_IncF, which showed a consistent trend towards higher
growth rates relative to the ESBL-plasmid-free S. Typhi-
murium recipient (Fig. 5B), but not for any plasmid in any
E. coli recipient population (Supplementary Results). This
indicates there was appreciable horizontal transfer (multiple
events) in the majority of combinations we tested. A third
process that potentially contributes to variable transconju-
gant frequencies is segregational plasmid loss. We did not
test this directly, but note that each ESBL-plasmid encodes
at least two TA-systems (Supplementary Fig. S10). We
would expect these to make plasmid loss from transconju-
gants infrequent [22].
In vivo, we investigated the effect of ESBL-plasmids
p4A_IncI and p8A_IncF on bacterial fitness with direct 1:1
competition between recipient RE3 and its transconjugants
(Fig. 5C). After 7 days of competition, for transconjugants
with p4A_IncI, there was no significant change in the
relative frequency of recipients to transconjugants. The
in vivo competition experiment revealed a growth advan-
tage of RE3 when carrying p8A_IncF, allowing a tenfold
relative increase of the initial transconjugant frequency
when growing for 7 days in the gut (from a 1:1 ratio to a
1:10 ratio of recipients to transconjugants, Fig. 5C).
Because we used oriT-mutants, no plasmid could be hor-
izontally transferred during this competition experiment and
therefore increasing transconjugant populations must have
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resulted from clonal growth. Allowing for horizontal plas-
mid transfer (7-day conjugation experiment), however, the
transconjugant frequency of RE2 and RE3 carrying
p8A_IncF increased from the detection limit of 10−6 up to
final frequencies of 1% (e.g. a 104-fold increase in relative
transconjugant population size; Fig. 4A,B). This large dif-
ference in transconjugant population increase with and
without conjugation allows us to conclude that in our gut
colonisation model without antibiotic selection, the spread
of ESBL-plasmids was driven mainly by conjugative
transfer, rather than by clonal expansion of transconjugants.
The fast increase of the transconjugant population RE3
carrying p4A_IncI within only eight hours (Supplementary
Fig. S15), despite a lack of growth advantage over recipient
RE3 (Fig. 5C), further supports this result. However, we
cannot exclude that clonal expansion did not contribute to
observed final transconjugant frequencies. In fact, we
expect that these are the result of both processes. For future
work it might be interesting to systematically assess if such
plasmid-mediated enhancement of host colonisation can
contribute to the spread of some antibiotic resistance plas-
mids. Altogether, we demonstrated that variable plasmid
spread probably resulted from variable transfer rates, that
horizontal transfer allows for rapid ESBL-plasmid spread in
the murine gut in the absence of antibiotic selection and that
in vivo plasmid spread can reflect in vitro transfer
dynamics.
Plasmid transfer genes and incompatibility are the
main genetic determinants of observed plasmid
spread
We showed that horizontal transfer is a crucial determinant
of the extent of ESBL-plasmid spread in vitro and in vivo
and that in both systems, variability in final transconjugant
frequencies across strain and plasmid combinations prob-
ably results from variable plasmid transfer rates. To explain
the variability in these transfer rates, we analysed genetic
factors of plasmids and donor and recipient strains that have
previously been described to independently influence plas-
mid transfer [11, 12, 21, 22, 13–20].
We found that only three out of the eight clinically
relevant ESBL-plasmids encoded all necessary tra genes to
initiate their own transfer (Fig. 6), suggesting only these
plasmids would be conjugative. Consistent with this, each
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(n= 4; beams are mean values
± SEM). Transconjugants and
their plasmid free complements
grew in independent cultures
and we calculated the relative
growth by dividing the
transconjugant growth rates
(h−1) by the mean growth-rate of
plasmid-free strains. C We
performed the competition
experiment by colonising the
mice with a 1:1 mix of a non-
conjugative transconjugant
(oriT-knockout) and recipient
RE3 (n= 6; 3 independent
transconjugants, n= 2 for each).
C Kruskal–Wallis test p > 0.05
(ns), p < 0.01 (**).
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recipients, whereas the other plasmids did not. This con-
firms the presence of essential tra genes on ESBL-plasmids
to be the main genomic factor predicting their spread and
the specific recipient strain to play a lesser role (Fig. 2).
However, also p3B_IncI, which lacks most of the essential
transfer genes, was transferred to RE2 in one of the six
replicate populations. Although this occurred in only one
replicate, this observation could warrant further work to see
if non-conjugative ESBL-plasmids can be efficiently
mobilised by conjugative plasmids present in donor or
recipient strains (Supplementary Table S1).
Because our statistical analyses of the variation in
plasmid spread after excluding non-conjugative plasmids
indicated a significant additional plasmid effect and con-
tributions of donor and recipient strains, we investigated the
genetic basis of this more fine-scale variation in plasmid
spread (Figs. 2, 3). The relatedness of plasmids in donor and
recipient strains with regard to their replicons was a crucial
determinant of the extent of plasmid spread. Plasmid
incompatibility likely explains why final transconjugant
frequencies of the IncFII ESBL-plasmids p5A_IncF and
p6A_IncI/F were highest with recipient RE1, the only
recipient without a plasmid encoding an IncFII-replicon,
and varied largely depending on recipients (Fig. 2). The
lack of transconjugants resulting from conjugation of donor
D6 carrying plasmid p6A_IncI/F with recipient RS, could
be due to the incompatibility with the resident plasmid
pRS_IncF. Further evidence for the role of incompatibility
comes from conjugation with plasmid p8A_IncF, which
carries half of the IncFIC-FII replicon (Supplementary
Fig. S7) and resulted in the loss of the resident F-plasmid
pRE3A_IncF in recipient RE3, both in vitro and in vivo
(Supplementary Table S2). Despite this plasmid inter-
ference in conjugation with RE3, plasmid p8A_IncF spread
in all recipients at the same rate (Fig. 2).
Additionally, we have investigated the role of (i) phy-
logenetic relatedness of the mating strains, (ii) immunity
systems such as RM and CRISPR-Cas systems, (iii) plasmid
co-transfer and (iv) mutational changes accumulating dur-
ing in vitro or in vivo conjugation assays in plasmid spread
(see Supplementary Results). Of all these factors only









































































































































































































Fig. 6 Transfer genes. Presence
(blue) or absence (white) of
essential tra genes for IncF
plasmids (A), and IncI plasmids
(B). Genes and panels in grey
are non-essential for pilus
biogenesis, DNA transfer or
conjugation, according to
Koraiman [51] (A) and Komano
[49, 50] (B). ESBL-plasmids are
indicated by an asterisk: green
indicates spread to multiple
recipient populations, orange
indicates conjugation with only
one replicate population, and red
indicates no transfer. Non-
ESBL-plasmids are labelled in
black. For the traY gene of the
IncI plasmids, we indicate
whether the gene found
corresponds to the version
carried by IncI1 or IncIγ
plasmids (white text in B).
Plasmid p6A_IncI/IncF is shown
on both A and B, but only the
IncI1 transfer system is
complete.
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correlated with a detectable effect on plasmid spread in our
in vitro and in vivo experiments.
Discussion
We demonstrated that in addition to the transferring plasmid
itself, strain aspects like the presence of plasmids in the
recipient, are also important determinants of plasmid spread
in the absence of antibiotic selection. This is consistent with
and extends past work [2, 25, 27, 34] by quantifying the
relative importance of donor, recipient and plasmid for the
spread of key clinical plasmids from their native bacterial
hosts. Moreover, the qualitative agreement between plasmid
spread in vitro and in our mouse model demonstrated that
these relative contributions are robust even in complex
environments, suggesting in vitro screening can enable
predictions of which plasmid–bacteria combinations will be
most successful in nature. A second key implication of our
results is that all of the ESBL-plasmids we tested that car-
ried genes known to encode conjugative transfer machinery
spread efficiently in various recipient populations, both
in vitro and in vivo without antibiotic selection (Figs. 2–4).
This shows predictions about the extent of plasmid spread
in the absence of antibiotics can be further improved using
sequence data annotated with information about conjugative
machinery.
Despite the agreement between our in vivo and in vitro
conditions, we stress that local abiotic conditions play a
crucial role for conjugation and for plasmid spread. For
instance, some plasmids can only transfer in a structured
environment, as in surface mating, while other plasmids
transfer at higher rates in well-mixed environments, as in
liquid mating cultures. This phenomenon has been linked to
pili flexibility [30, 31]. Whether the conjugative environ-
ment of the mammalian gut lumen resembles more a
structured or a well-mixed environment is currently not
clear. In the colonisation model we used for our conjugation
experiments [58], interactions of bacteria with the host
intestinal lining might allow for more structured populations
[85]. Observed dynamics of plasmid p4_IncI indeed high-
lights a potential importance of structured environment for
conjugation in vivo (Fig. 4). In combination with recipient
RE3, plasmid p4A_IncI spread remarkably fast, reaching a
transconjugant frequency of 1% already after 8 h (Supple-
mentary Fig. S15). This transconjugant frequency was more
than 100-fold higher compared to when p4A_IncI spread in
recipient population RE2, a difference consistent with our
in vitro surface mating experiment (Supplementary
Fig. S12). This recipient-dependent difference further
highlights the importance of host-encoded factors that can
potentially influence plasmid spread in vivo. We speculate
that such a factor might be the gene iha carried by RE3,
which encodes an adherence-conferring molecule [86] and
could influence its spatial organisation in the gut (Supple-
mentary Fig. S6). Another indication for a fixed spatial
structure of RE3, in fact of a spatially heterogenous struc-
ture of the involved bacterial populations, is the plateau the
transconjugants of RE3 with p4A_IncI reach after 24 h [87].
Indeed, spatially distinct niches in the gut can exist and lead
to differential growth or survival of E. coli strains [88].
Alternative explanations for this could be the out-
competition of recipient and transconjugant populations
by the plasmid donor strain, through either a direct inter-
action or an indirect ecological effect via interaction with
microbiota members, or a reduced growth rate after initial
colonisation of the plasmid donor strain. The waning
population size of the recipients (Supplementary Fig. S14)
may indeed influence the transconjugant population, and
could be facilitated by T6SS-mediated killing (as RE3 does
not contain a T6SS). This, however, seems unlikely as the
sole cause of plasmid spread dynamics in RE3, because we
would expect this to lead to a similar pattern with plasmid
p8A_IncF from donor D8. We propose that surface mating
could play an important role for plasmid spread in vivo and
emphasise the need for future studies addressing this.
Based on bioinformatic analysis we investigated a
potential role of further strain-specific features on plasmid
spread. Bacterial defence systems can affect the efficiency
of plasmid transfer [19] and all four recipient strains encode
the adaptive immunity system CRISPR-Cas Type I, of
which Type IF (recipients RE1 and RE2) is commonly
associated with antimicrobial susceptibility in E. coli [89]
(Supplementary Table S4). In laboratory E. coli strains such
as K12, Type I CRISPR-Cas loci are considered to be
inactive under laboratory growth conditions [90]. This is
consistent with the observed lack of spacer acquisition in
the laboratory for our natural strains. Further, it has been
proposed that plasmid transfer to close kin is more efficient
due to the similarity in RM systems of donor and recipient
strains [28]. Here, based on presence and absence of RM
systems, we did not find this relation. Our ESBL-plasmids,
like many other conjugative plasmids [91], employ anti-
restriction strategies and thus, we and others [92, 93] sug-
gest that RM systems may only marginally shape horizontal
plasmid transfer in natural systems, although to fully
address this question a different experimental design would
be required, using simpler conjugation assays and a much
larger number of strains.
Our results also imply that interaction of plasmids pre-
sent in donor and recipient strains can play a key role in
their spread. This is important because in natural systems
bacteria often harbour multiple plasmids. We found plasmid
incompatibility to limit but not completely prevent plasmid
transfer in conjugation with ST131 strains D5 and D6
(Fig. 2). This permeability probably results from the
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multiple replicons encoded on these ESBL-plasmids, a
mechanism that could allow plasmids to transfer in spite of
incompatibility [94]. Co-transfer of other plasmids is com-
mon, and has been proposed to affect plasmid transfer rates
[14, 15, 95, 96]. We found little plasmid co-transfer and
could not relate its occurrence to the observed plasmid
spread (Supplementary Results and Table S2). Sequencing
of the ESBL-plasmids in transconjugants revealed no
mutations after transfer (Supplementary Results and Sup-
plementary Table S2). This is in agreement with earlier
findings reporting the absence of mutations on ESBL-
plasmids even after 112 days of evolution of transconju-
gants [97] but does not exclude that such adaptive processes
have happened in the past. Regardless, these data suggest
that contemporary clinical ESBL-plasmids are well adapted
to Enterobacteriaceae and do not require clone-specific
adaptations for successful spread.
Given the central role of plasmids in the global dis-
semination of antibiotic resistance, it is of great importance
to understand the factors contributing to plasmid spread
under natural conditions. We demonstrated that in addition
to the plasmid, strain aspects are key for plasmid spread in a
complex mouse model. Crucially, we demonstrated this
with natural, clinically relevant plasmid–strain combina-
tions. Moreover, our study suggests large-scale in vitro
conjugation experiments and genetic data, particularly
annotated with information about plasmid conjugation
machinery, can enable predictions about which plasmids
will spread most rapidly and in which host strains in the gut
environment of animals and humans. Ultimately, along with
others [8], we advocate that early detection of successful
strain–plasmid associations may allow for interventions that
impede the emergence of pandemic strain–plasmid
associations.
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